669 related articles for article (PubMed ID: 34452439)
1. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
3. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
5. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
[TBL] [Abstract][Full Text] [Related]
6. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
[TBL] [Abstract][Full Text] [Related]
7. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment.
Kong D; Yang Z; Li G; Wu Q; Gu Z; Wan D; Zhang Q; Zhang X; Cheng S; Liu B; Zhang K; Zhang W
BMC Med; 2022 Oct; 20(1):376. PubMed ID: 36310169
[TBL] [Abstract][Full Text] [Related]
8. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
11. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
[TBL] [Abstract][Full Text] [Related]
12. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.
Marelli G; Howells A; Lemoine NR; Wang Y
Front Immunol; 2018; 9():866. PubMed ID: 29755464
[TBL] [Abstract][Full Text] [Related]
14. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
15. Cutting both ways: the innate immune response to oncolytic virotherapy.
Mealiea D; McCart JA
Cancer Gene Ther; 2022 Jun; 29(6):629-646. PubMed ID: 34453122
[TBL] [Abstract][Full Text] [Related]
16. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
18. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
[TBL] [Abstract][Full Text] [Related]
19. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment.
Jamieson TR; Poutou J; Ilkow CS
Cytokine Growth Factor Rev; 2020 Dec; 56():102-114. PubMed ID: 32958389
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Chen L; Zuo M; Zhou Q; Wang Y
Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
